A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Recruiting · Phase 3 · NCT06290141
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
At a glance
- Research payments reported, 2025
- $703,523
- U.S. investigators named
- 20
- Sites paid
- 23
- Planned or actual enrollment
- 160
About the trial
- Sponsor
- Sanofi
- Tested
- riliprubart (drug), Placebo (drug), riliprubart (drug), Placebo (drug), IVIg (drug), Placebo (drug)
- Dates
- Started 2024-08-21; completion 2029-01-12
- Results posted
- Not yet
The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.
From ClinicalTrials.gov, last updated 2026-10-19. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $703,523 in research payments for this study in 2025 (57 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- John B. Riser, MD Specialist · Birmingham, AL
- Suraj A. Muley, MD Neurology · Phoenix, AZ
- Said R. Beydoun, M.D. Neurology · Los Angeles, CA
- Jeffrey Mullen, MD Physical Medicine & Rehabilitation (PM&R) · Orange, CA
- Bhaskar Roy, MBBS Physical Medicine & Rehabilitation (PM&R) · New Haven, CT
- Anita M. Fletcher, M.D. Neurology · Orlando, FL
- Mamatha Pasnoor, MD Neurology · Kansas City, KS
- Ehtesham Khalid, M.D, MRCP, FCPS Physical Medicine & Rehabilitation (PM&R) · New Orleans, LA
- Reza Seyedsadjadi, M.D. Neurology · Boston, MA
- Ahmet Hoke, M.D. Neurology · Baltimore, MD
- Amit Sachdev, M.D., MS Neurology · East Lansing, MI
- Lawrence A. Zeidman, M.D. Neurology · Detroit, MI
- Charles A. Roach, MD Neurology · Saint Louis, MO
- Thomas H. Brannagan III, MD Neurology · New York, NY
- Bennett Myers, M.D. Neurology · Amherst, NY
- Anthony P. Zampino Student in an Organized Health Care Education/Training Program · Cleveland, OH
- Chafic Karam, M.D. Neurology · Portland, OR
- Yessar M. Hussain, M.D. Physical Medicine & Rehabilitation (PM&R) · Austin, TX
- Matthew P. Elliott, MD Neurology · Charlottesville, VA
- Rup Tandan, M.D., FRCP Neurology · Burlington, VT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Virginia $132,506
- Alabama Neurology Associates PC $72,409
- Hospital of Univ of Pennsylvania, PA $61,221
- Uci Health-Orange, CA $45,214
- Yale University Attn Treasury Services $38,012
- National Neuromuscular Research Institute PLLC $37,500
- Johns Hopkins University $35,135
- Henry Ford Health Hospital, MI $32,400
- Michigan State University Center for Bleeding and Cloting Dis $32,276
- Uh Cleveland Medical Center, OH $31,720
- University of Kansas Medical Center Research Inst Inc $30,950
- The Trustees of Columbia University Y in The City of New York Columbia Technology Ventures $23,278
- Ochsner Medical Center Acute, LA $23,100
- Massachusetts General Hospital Attn Research Finance Attn 2021a $18,800
- Washington University $18,732
- Hospital for Special Surgery, NY $18,655
- Dent Neurosciences Research Center Inc $14,785
- Univ. of Vermont - Fletcher Allen Health Care, VT $14,730
- Northshore University Healthsystem - Evanston Hospital, IL $13,550
- University of Southern California $4,000
- Keck Hospital of Usc, CA $2,950
- Honorhealth Scottsdale Osborn Medical Center, AZ $1,000
- Adventhealth Orlando, FL $600
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.